Lupin Ltd (LUPIN):企業の財務・戦略的SWOT分析

【英語タイトル】Lupin Ltd (LUPIN) - Financial and Strategic SWOT Analysis Review

GlobalDataが出版した調査資料(DATA904C0592)・商品コード:DATA904C0592
・発行会社(調査会社):GlobalData
・発行日:2018年7月
・ページ数:57
・レポート言語:英語
・レポート形式:PDF
・納品方法:Eメール
・産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD125 ⇒換算¥13,375見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD250 ⇒換算¥26,750見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD375 ⇒換算¥40,125見積依頼/購入/質問フォーム
販売価格オプションの説明
※お支払金額:換算金額(日本円)+消費税
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000を加算
※納期:即日〜2営業日(3日以上かかる場合は別途表記又はご連絡)
※お支払方法:納品日+5日以内に請求書を発行・郵送(請求書発行日より2ヶ月以内に銀行振込、振込先:三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能)
【レポートの概要】

Lupin Ltd (LUPIN) – Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.
The profile contains critical company information including:

- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Key manufacturing facilities – A list of key manufacturing facilities of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Lupin Ltd (Lupin) focuses on the development and manufacture of generic and branded formulations, biotechnology products and active pharmaceutical ingredients (APIs). The company has expertise in the areas of cardiovascular, asthma, diabetology, pediatrics, central nervous system, gastro-intestinal, anti-infectives, nonsteroidal anti-inflammatory drugs (NSAIDs), anti-TB and cephalosporins. It undertakes extensive research and development of pharmaceuticals for treatment of migraine, gastrointestinal, psoriasis, central nervous system, cardiovascular, tuberculosis, diabetes and inflammation. Lupin develops value-added generic pharmaceuticals based on its platform technologies. The company along with its subsidiaries has manufacturing facilities in India, the US, Japan, Mexico and Brazil. Lupin is headquartered in Mumbai, Maharashtra, India.

Lupin Ltd Key Recent Developments

Jul 16,2018: Lupin’s Goa facility gets approval from UK MHRA
Jul 10,2018: Lupin appoints Yashwant Mahadik as President – Global HR
Jul 05,2018: Trend Micro secures Lupin’s vast IT environment
Jun 29,2018: Lupin announces tie-up with European Association of Urology (EAU)
May 31,2018: Lupin appoints Nicholas Hart as President – Specialty for US Business

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Section 1 – About the Company 6
Lupin Ltd – Key Facts 6
Lupin Ltd – Key Employees 7
Lupin Ltd – Key Employee Biographies 9
Lupin Ltd – Major Products and Services 10
Lupin Ltd – History 11
Lupin Ltd – Company Statement 19
Lupin Ltd – Locations And Subsidiaries 20
Head Office 20
Other Locations & Subsidiaries 20
Joint Venture 23
Section 2 – Company Analysis 24
Company Overview 24
Lupin Ltd – Business Description 25
R&D Overview 25
Lupin Ltd – Corporate Strategy 26
Lupin Ltd – SWOT Analysis 27
SWOT Analysis – Overview 27
Lupin Ltd – Strengths 27
Lupin Ltd – Weaknesses 28
Lupin Ltd – Opportunities 29
Lupin Ltd – Threats 30
Lupin Ltd – Key Competitors 31
Section 3 – Company Financial Ratios 32
Financial Ratios – Capital Market Ratios 32
Financial Ratios – Annual Ratios 33
Performance Chart 36
Financial Performance 36
Financial Ratios – Interim Ratios 37
Financial Ratios – Ratio Charts 38
Section 4 – Company’s Lifesciences Financial Deals and Alliances 39
Lupin Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 39
Lupin Ltd, Pharmaceuticals & Healthcare, Deals By Type, 2012 to YTD 2018 40
Lupin Ltd, Recent Deals Summary 41
Section 5 – Company’s Recent Developments 42
Jul 16, 2018: Lupin’s Goa facility gets approval from UK MHRA 42
Jul 10, 2018: Lupin appoints Yashwant Mahadik as President – Global HR 43
Jun 29, 2018: Lupin announces tie-up with European Association of Urology (EAU) 44
May 31, 2018: Lupin appoints Nicholas Hart as President – Specialty for US Business 45
May 15, 2018: Lupin announces fiscal year 2018 Results, Board recommends dividend of 250% 46
May 14, 2018: Lupin’s Nagpur facility US FDA inspection concluded with no observations 48
May 10, 2018: Lupin launches Corcal Bone and Beauty supplement 49
Apr 09, 2018: Lupin’s Softovac in The Economic Times ‘Promising Brands of 2018’ 50
Apr 09, 2018: Lupin’s Softovac In Economic Times ‘Promising Brands Of 2018 51
Apr 06, 2018: Lupin’s Pithampur Unit 1 facility receives Establishment Investigation report (EIR) from US FDA 52
Section 6 – Appendix 53
Methodology 53
Ratio Definitions 53
About GlobalData 57
Contact Us 57
Disclaimer 57

List of Tables
Lupin Ltd, Key Facts 6
Lupin Ltd, Key Employees 7
Lupin Ltd, Key Employee Biographies 9
Lupin Ltd, Major Products and Services 10
Lupin Ltd, History 11
Lupin Ltd, Other Locations 20
Lupin Ltd, Subsidiaries 20
Lupin Ltd, Joint Venture 23
Lupin Ltd, Key Competitors 31
Lupin Ltd, Ratios based on current share price 32
Lupin Ltd, Annual Ratios 33
Lupin Ltd, Annual Ratios (Cont...1) 34
Lupin Ltd, Annual Ratios (Cont...2) 35
Lupin Ltd, Interim Ratios 37
Lupin Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 39
Lupin Ltd, Pharmaceuticals & Healthcare, Deals By Type, 2012 to YTD 2018 40
Lupin Ltd, Recent Deals Summary 41
Currency Codes 53
Capital Market Ratios 53
Equity Ratios 54
Profitability Ratios 54
Cost Ratios 55
Liquidity Ratios 55
Leverage Ratios 56
Efficiency Ratios 56

List of Figures
Lupin Ltd, Performance Chart (2014 - 2018) 36
Lupin Ltd, Ratio Charts 38
Lupin Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 39
Lupin Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 40

★調査レポート[Lupin Ltd (LUPIN):企業の財務・戦略的SWOT分析] (コード:DATA904C0592)販売に関する免責事項を必ずご確認ください。
★調査レポート[Lupin Ltd (LUPIN):企業の財務・戦略的SWOT分析]についてメールでお問い合わせ


◆H&Iグローバルリサーチのお客様(例)◆